These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24337181)

  • 1. Public-private relationships in biobanking: a still underestimated key component of open innovation.
    Hofman P; Bréchot C; Zatloukal K; Dagher G; Clément B
    Virchows Arch; 2014 Jan; 464(1):3-9. PubMed ID: 24337181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Academic Biobanks in Public-Private Partnerships in the European Biobanking and BioMolecular Resources Research Infrastructure Community.
    Hämäläinen I; Törnwall O; Simell B; Zatloukal K; Perola M; van Ommen GB
    Biopreserv Biobank; 2019; 17(1):46-51. PubMed ID: 30499696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Professional translational research: a new hybrid paradigm in early drug discovery.
    Nussbaumer P; Klebl B
    Future Med Chem; 2015; 7(14):1879-89. PubMed ID: 26420644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public-private partnership models in France and in Europe.
    Demotes-Mainard J; Canet E; Segard L
    Therapie; 2006; 61(4):325-34, 313-23. PubMed ID: 17124948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of public-private partnerships in addressing the biomedical innovation challenge.
    Said M; Zerhouni E
    Nat Rev Drug Discov; 2014 Nov; 13(11):789-90. PubMed ID: 25359362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Future of Biobanking: A Conceptual Look at How Biobanks Can Respond to the Growing Human Biospecimen Needs of Researchers.
    Somiari SB; Somiari RI
    Adv Exp Med Biol; 2015; 864():11-27. PubMed ID: 26420610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four disruptive strategies for removing drug discovery bottlenecks.
    Ekins S; Waller CL; Bradley MP; Clark AM; Williams AJ
    Drug Discov Today; 2013 Mar; 18(5-6):265-71. PubMed ID: 23098820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open innovation networks between academia and industry: an imperative for breakthrough therapies.
    Melese T; Lin SM; Chang JL; Cohen NH
    Nat Med; 2009 May; 15(5):502-7. PubMed ID: 19424212
    [No Abstract]   [Full Text] [Related]  

  • 10. Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact.
    de Vrueh RLA; Crommelin DJA
    Pharm Res; 2017 Oct; 34(10):1985-1999. PubMed ID: 28589444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BBMRI-ERIC as a resource for pharmaceutical and life science industries: the development of biobank-based Expert Centres.
    van Ommen GJ; Törnwall O; Bréchot C; Dagher G; Galli J; Hveem K; Landegren U; Luchinat C; Metspalu A; Nilsson C; Solesvik OV; Perola M; Litton JE; Zatloukal K
    Eur J Hum Genet; 2015 Jul; 23(7):893-900. PubMed ID: 25407005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intellectual property policies in early-phase research in public-private partnerships.
    Stevens H; Van Overwalle G; Van Looy B; Huys I
    Nat Biotechnol; 2016 May; 34(5):504-10. PubMed ID: 27153280
    [No Abstract]   [Full Text] [Related]  

  • 13. Public-private partnerships in translational medicine: concepts and practical examples.
    Luijten PR; van Dongen GA; Moonen CT; Storm G; Crommelin DJ
    J Control Release; 2012 Jul; 161(2):416-21. PubMed ID: 22465390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PCAST report: impact and implications for the pharmaceutical industry.
    Morris SA; Rosenblatt M; Orloff JJ; Lewis-Hall F; Waldstreicher J
    Clin Pharmacol Ther; 2013 Sep; 94(3):300-2. PubMed ID: 23963216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to set up collaborations between academia and industrial biotech companies.
    Pronk JT; Lee SY; Lievense J; Pierce J; Palsson B; Uhlen M; Nielsen J
    Nat Biotechnol; 2015 Mar; 33(3):237-40. PubMed ID: 25748909
    [No Abstract]   [Full Text] [Related]  

  • 16. How to create innovation by building the translation bridge from basic research into medicinal drugs: an industrial perspective.
    Germann PG; Schuhmacher A; Harrison J; Law R; Haug K; Wong G
    Hum Genomics; 2013 Mar; 7(1):5. PubMed ID: 23496921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the complex relationships among actors involved in the implementation of public-private mix (PPM) for TB control in India, using social theory.
    Salve S; Harris K; Sheikh K; Porter JDH
    Int J Equity Health; 2018 Jun; 17(1):73. PubMed ID: 29880052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The academic-industrial complex: navigating the translational and cultural divide.
    Freedman S; Mullane K
    Drug Discov Today; 2017 Jul; 22(7):976-993. PubMed ID: 28336175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Narrowing the translational research gap: what needs to be done?
    Wolkowicz R
    Future Med Chem; 2015; 7(14):1843-6. PubMed ID: 26393393
    [No Abstract]   [Full Text] [Related]  

  • 20. Leveraging crowdsourcing to facilitate the discovery of new medicines.
    Norman TC; Bountra C; Edwards AM; Yamamoto KR; Friend SH
    Sci Transl Med; 2011 Jun; 3(88):88mr1. PubMed ID: 21697527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.